Subharekha Raghavan

Executive Director, HTE and Lead Discovery Capabilities, Merck Sharp & Dohme
When
17th-18th Sep 2018
Registration from 8am
Where
Boston, USA
Hyatt Regency Boston Harbor
Global Engage is pleased to announce as part of their Drug Discovery Series of events, The Medicinal Chemistry Summit: USA which will be held on September 17th – 18th 2018 in Boston, USA. This event will be the sister meeting to their successful European Medicinal Chemistry Summit of 2017.
Designed to attract experts working in all areas of medicinal chemistry, the Summit has three tracks focusing on key topics such as hit-to-lead optimization, target validation, the implementation of artificial intelligence into the drug discovery process, small molecule immuno-oncology, small molecule targeting of RNA, ADCs and SBDD. In addition, this conference will have an entire day focused on the enabling technologies revolutionizing medicinal chemistry – protein degradation and DNA encoded libraries. The Summit will provide a forum to network, learn, and engage with senior representatives of leading pharmaceutical and biotech companies worldwide.
This comprehensive two-day summit, featuring over 35 presentations will provide experts with an exceptional environment in which to debate the key issues facing them today. These include: optimizing hit to lead quality and timescale, protein degradation, DNA encoded libraries, small molecule immuno-oncology research, SBDD, and the use of AI in the drug discovery process.
An extended panel discussion will explore the future of medicinal chemistry, while 7 roundtable discussions, led by experts, will enable a deeper investigation of subjects including DNA encoded libraries, artificial intelligence in medicinal chemistry and predictive toxicology – improving compound safety.
Sign up to receive updates, news and speaker resources
Vice President, Discovery Chemistry & Technologies, & Distinguished Research Fellow, AbbVie
CSO, Cloud Pharmaceuticals
Senior Director of Drug Discovery Technologies, Nurix Therapeutics
Founder & Chief Technology Officer, Kymera Therapeutics
Senior Vice President, Science, Schrödinger
Team Leader, Computational Chemistry, Selvita
Product Manager, Sample Management & Drug Discovery, TTP Labtech
Vice President of Medicinal Chemistry
Vice President of Molecular Discovery, Ribon Therapeutics
Director of Alliance Management and Sourcing, External Research Solutions, Pfizer
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School & Dana Farber Cancer Institute
Senior Vice President and Site Head, Boston Research, Vertex
Director of Medicinal Chemistry, SAGE Therapeutics
Senior Director, Arvinas
Executive Director, HTE and Lead Discovery Capabilities, Merck Sharp & Dohme
Associate Principal Scientist, Astrazeneca
ELF Head of Chemistry & CEO of Taros Chemicals
Senior Vice President of Chemistry, X-Chem
Executive Director, Chemistry, H3 Biomedicine
Vice President of Medicinal Chemistry, Jubilant Biosys
Senior Vice President, CMC, IP, Xenon Pharmaceuticals
Founder & Chief Scientific Officer, Arrakis Therapeutics
Senior Director of Oncology Chemistry, Takeda Pharmaceuticals
Senior Research Scientist, Early CVRM Medicinal Chemistry, R&D Biopharmaceuticals, AstraZeneca
Manager & Chemistry Group Leader, GlaxoSmithKline
Director in Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb
Principal Investigator, Chemical Biology Laboratory, National Cancer Institute
Senior Investigator I, Novartis
Vice President of Chemistry, RA Pharma
Senior Director, Pfizer
Director, Predictive Compound ADME and Safety, AstraZeneca
Founder & Chief Scientific Officer, DiCE Molecules
President & CEO, C4 Therapeutics
Senior Director, WuXi AppTec
Vice President, Discovery Chemistry & Technologies, & Distinguished Research Fellow, AbbVie
CSO, Cloud Pharmaceuticals
Senior Director of Drug Discovery Technologies, Nurix Therapeutics
Founder & Chief Technology Officer, Kymera Therapeutics
Senior Vice President, Science, Schrödinger
Team Leader, Computational Chemistry, Selvita
Product Manager, Sample Management & Drug Discovery, TTP Labtech
Vice President of Medicinal Chemistry
Vice President of Molecular Discovery, Ribon Therapeutics
Director of Alliance Management and Sourcing, External Research Solutions, Pfizer
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School & Dana Farber Cancer Institute
Senior Vice President and Site Head, Boston Research, Vertex
Director of Medicinal Chemistry, SAGE Therapeutics
Senior Director, Arvinas
Executive Director, HTE and Lead Discovery Capabilities, Merck Sharp & Dohme
Associate Principal Scientist, Astrazeneca
ELF Head of Chemistry & CEO of Taros Chemicals
Senior Vice President of Chemistry, X-Chem
Executive Director, Chemistry, H3 Biomedicine
Vice President of Medicinal Chemistry, Jubilant Biosys
Senior Vice President, CMC, IP, Xenon Pharmaceuticals
Founder & Chief Scientific Officer, Arrakis Therapeutics
Senior Director of Oncology Chemistry, Takeda Pharmaceuticals
Senior Research Scientist, Early CVRM Medicinal Chemistry, R&D Biopharmaceuticals, AstraZeneca
Manager & Chemistry Group Leader, GlaxoSmithKline
Director in Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb
Principal Investigator, Chemical Biology Laboratory, National Cancer Institute
Senior Investigator I, Novartis
Vice President of Chemistry, RA Pharma
Senior Director, Pfizer
Director, Predictive Compound ADME and Safety, AstraZeneca
Founder & Chief Scientific Officer, DiCE Molecules
President & CEO, C4 Therapeutics
Senior Director, WuXi AppTec
This comprehensive two-day summit, featuring over 35 presentations will provide experts with an exceptional environment in which to debate the key issues facing them today.
The agenda includes an extended panel discussion that will explore the future of medicinal chemistry, while 7 roundtable discussions, led by experts, will enable a deeper investigation of subjects including DNA encoded libraries, artificial intelligence in medicinal chemistry and predictive toxicology – improving compound safety.
Download the agendaGet news about exciting developments in Medicinal Chemistry research and product development direct to your inbox.
Hyatt Regency Boston Harbor
101 Harborside Drive
Boston, Massachusetts, USA, 02128
A Unique Boston Harbor Hotel
Hyatt Regency Boston Harbor is an intimate and boutique-style Harborside hotel with breathtaking views of the beautiful city skyline. Guests will appreciate the proximity to Logan Airport and the hotel’s complimentary airport shuttle. Boston’s famed cultural and historical sites, recreational options, and neighborhoods are just minutes away and easily accessible through our many public transportation options available including of the MBTA Train and Water Taxi.
3 for the price of 2 offer
Discount applied automatically when registering 3 places at once.
Not applicable for solution provider companies or compatible with any other offers or discount codes.
All conference sessions
Lunches and refreshments
Access to exhibition room
All networking forums
Conference workbook
e-documentation pack
Option 1 – Please phone +44 (0) 1865 849841 and we will take your details over the phone
Option 2 – Please complete the form below to pay online
Jubilant Biosys is a subsidiary of Jubilant Life Sciences, a global integrated life sciences company. The company offers standalone and collaborative integrated drug discovery services with clear focus in Oncology, Metabolic Disorders, Pain & Inflammation, CNS therapeutic areas with augmented additional chemistry capacity. Jubilant Biosys is committed to global innovation and carries out proprietary discovery programs for out licensing to global pharmaceuticals and biotechnology companies.
http://www.jubilantbiosys.com/
×Schrödinger is a science and technology leader in developing chemical simulation software aimed at transforming drug discovery research. The company’s products are used by nearly all the top pharmaceutical companies worldwide. Schrödinger also engages in drug discovery collaborations utilizing its best-in-class software solutions for modelling small molecules and protein therapeutics.
×TTP Labtech has discovery accelerating solutions for medicinal Chemists. The “mosquito” nL liquid handler enables 10-100 fold increase in analog synthesis and testing. “lab2lab” increases LCMS productivity by up to 300% directly submitting samples from the bench to remote analysis (including NMR)
×Selvita provides a broad spectrum of drug discovery services to expedite our biotech and pharma client’s delivery of new drugs to patients.
The industry experience of our multi-disciplinary team of scientists, together with Selvita’s close collaboration engagement model, enable us to act as a true extension of our clients team for:
PharmaResources is a leading Contract Research Organization (CRO) based in Shanghai, specializing in small molecule R&D and medicinal chemistry. Founded in 2007, PharmaResources has rapidly grown from five employees to over 400. We have built a team with an ingrained culture of supporting our clients, implemented clearly articulated program management processes that together enable highly successful project outcomes. We have the state-of-the-art laboratories and manufacturing facilities and service clients in biotech, start-ups and pharmaceutical clients.
http://www.pharmaresources.cn/
×HitGen Ltd, a biotech company located in China, is specialized in drug discovery and development based on its DNA Encoded Library technology platform. Our DNA encoded libraries currently own hundreds of billions of small molecules with novel, diverse and drug-like structures, which can be accessed by partners to identify new hit and lead compounds against a variety of target classes. Over 50 collaborations have been signed since 2016 including several top 10 Pharmas.
×X-Chem, Inc. is a privately owned biotechnology company based in Waltham, Massachusetts. The company’s mission is to apply its powerful DNA-encoded DEXTM product engine to the discovery of small molecule leads against high-value therapeutic targets. X-Chem has established partnerships with half of top-20 pharma, many biotechnology organizations, and several academic centers, and has licensed over 40 drug discovery programs to these partners.
×American Pharmaceutical Review is a journal covering the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies
×An STM journal publisher of online and print and open access journals, and related print/online book series, Bentham Science answers the informational needs of the pharmaceutical, biomedical and medical research community.
×Global Information, Inc. is an information service company holding offices in 6 countries and have sales agency contracts with over 300 research companies around the world. We sell 30,000 market research reports published by these publishers and accept custom-made researches.
×IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.
×IJCIH is a fully-refereed international journal publishing original articles concerning the theory and application of the computer to biomedicine and healthcare, with emphasis on novel approaches of wide healthcare significance.
×The objective of IJDMB is to facilitate collaboration between data mining researchers and bioinformaticians by presenting cutting-edge research topics and methodologies in the area of data mining for bioinformatics. This perspective acknowledges the inter-disciplinary nature of research in data mining and bioinformatics and provides a unified forum for researchers/practitioners/students/policy makers to share the latest research and developments in this fast-growing multi-disciplinary research area.
×Facilitating transformation from data to information to knowledge is paramount for organisations. Companies are flooded with data and conflicting information, but with limited real usable knowledge. However, rarely should a process be looked at from limited angles or in parts. Isolated islands of data mining, modelling and management (DMMM) should be connected. IJDMMM highlightes integration of DMMM, statistics/machine learning/databases, each element of data chain management, types of information, algorithms in software; from data pre-processing to post-processing; between theory and applications.
×IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.
×MedChemNet is an online community that provides a platform for researchers, opinion leaders and experts in the field to collaborate and access exclusive features, multimedia content, articles and news updates. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues.
×Pharma Journalist is a paramount B2b online magazine platform exhibiting targeted and succinct information concerning the world of Pharmaceutical Industry, therefore, keeping a tab on the updated and latest updates and trends concerning the field.
דIn the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers.
×Pink Medico – Medical and Healthcare Magazine (Print & Digital Version). We educate and empower consumers through our portal with latest news and trends, updates of medical and healthcare providers, pharma companies, new research and technologies, Medical Tourism… We are a revolutionary medical and healthcare aggregator that supports complete healthcare and allied services. We create a 360-degree approach towards quality healthcare service and ensure a wide range of people understand and avail healthcare easily. We are also NABH (National Accreditation Board for Hospitals and Healthcare Providers, India) Accredited Medical Tourism Facilitator.
×The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.
Since 2014 the SBA is consortia member of Ecobiofor, a FP7 project with researcher organizations, biotech and paint associations and pains SME’s developing bio-based solvents using green chemistry and biotechnology.
×Technology Networks is an internationally recognised, online publisher that provides access to the latest scientific news, products, research, videos and posters. Our global community is made up of over 300,000 researchers and scientific professionals from the life science, drug discovery and analytical arenas. Our portfolio of 30 communities are available free of charge on TechnologyNetworks.com
×Our sponsorship packages offer a wide range of attendance options to suit your budget and business needs in order to maximize return on investment.
If there is any other way you would like to sponsor or increase branding for your company at the event, please get in touch and we will be able to offer you a bespoke service.
Select which delegates you would like to meet in a series of prearranged twenty-minute one-to-one meetings, held during breakout sessions from the main conference agenda. Our conference team will be available at the sessions to ensure all your meetings take place on time.
Host your own half or full day pre or post event workshop to a dedicated audience around a subject of your choice. Global Engage will assist with the marketing of your workshop to provide a guaranteed audience.
Market to our event database and / or increase brand awareness through taking a poster position or sponsoring one of the refreshment breaks, lunches, drinks receptions or poster sessions. This can be supplemented by branding options such as placing your logo on the attendee lanyards or conference bags.
Showcase your technologies and products throughout the conference in the dedicated exhibition areas where all refreshment breaks and lunches take place, as well as the networking drinks reception at the end of day one.
Options include:
For further details please contact
Tony Couch / Faizel Ismail
Telephone +44 (0) 1865 849841 or
email [email protected]
Call us on +44 (0)1865 849 841
For details on attendees, packages and new opportunities, please contact our sponsorship team who will quickly provide everything you need to assess the conference for yourself.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.